SinoMab BioScience VE/BAIIA
Quel est le VE/BAIIA de SinoMab BioScience?
Le VE/BAIIA de SinoMab BioScience Limited est N/A
Quelle est la définition de VE/BAIIA?
VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
VE/BAIIA des entreprises dans Health Care secteur sur HKSE par rapport à SinoMab BioScience
Que fait SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Entreprises avec ve/baiia similaire à SinoMab BioScience
- Novavax a VE/BAIIA de N/A
- Cazaly Resources a VE/BAIIA de N/A
- DC Acquisition a VE/BAIIA de N/A
- Macarthur Minerals a VE/BAIIA de N/A
- Sierra Madre Gold and Silver a VE/BAIIA de N/A
- Rathdowney Resources a VE/BAIIA de N/A
- SinoMab BioScience a VE/BAIIA de N/A
- Big Dougie Capital a VE/BAIIA de N/A
- Income Trust a VE/BAIIA de N/A
- Aloro Mining a VE/BAIIA de N/A
- Manganese X a VE/BAIIA de N/A
- Coho Collective Kitchens a VE/BAIIA de N/A
- Viva Gold a VE/BAIIA de N/A